Heidelberg Pharma AG (ETR:HPHA)
Germany · Delayed Price · Currency is EUR 2.080
-0.070 (-3.26%)
Oct 26, 2026, 5:35 PM CET
Heidelberg Pharma AG Revenue
Heidelberg Pharma AG had revenue of 1.92M EUR in the quarter ending August 31, 2026, with 3,974.11% growth. This brings the company's total for the last twelve months to 9.32M, up 206.78% year-over-year. In the fiscal year ending November 30, 2025, Heidelberg Pharma AG had annual revenue of 1.46M, down -78.72%. That makes Heidelberg Pharma AG the 37,180th largest company in the world by revenue and 517th in Germany.
Revenue (ttm)
9.32M
Revenue Growth
+206.78%
P/S Ratio
10.44
Revenue / Employee
282.37K
Employees
33
Market Cap
97.31M
Revenue by Geography
- China 1.17M 80.1%
- USA 285.00K 19.5%
- Germany 5.00K 0.3%
Fiscal year ended Nov 30, 2025 See the full Heidelberg Pharma AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 1.46M | -5.39M | -78.72% |
| Nov 30, 2024 | 6.85M | -3.01M | -30.53% |
| Nov 30, 2023 | 9.86M | -8.66M | -46.75% |
| Nov 30, 2022 | 18.51M | 16.48M | 810.30% |
| Nov 30, 2021 | 2.03M | -6.63M | -76.53% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| MEDICLIN Aktiengesellschaft | 819.84M |
| FamiCord AG | 87.78M |
| LIMES Schlosskliniken AG | 56.72M |
| DocCheck AG | 56.65M |
Heidelberg Pharma AG News
- 11 days ago - EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026 - Wallstreet:Online
- 11 days ago - Heidelberg Pharma AG Earnings release: Q3 2026 - Filings
- 1 month ago - EQS-Adhoc: Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates - Wallstreet:Online
- 3 months ago - Heidelberg Pharma AG Quarterly report: Q2 2026 - Filings
- 3 months ago - EQS-News: Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business - Wallstreet:Online
- 6 months ago - EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026 - Wallstreet:Online
- 6 months ago - Heidelberg Pharma AG Earnings release: Q1 2026 - Filings
- 6 months ago - EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101 - Wallstreet:Online